ADAMTS Revenge on Eve?

REFERENCES

1. 1.↵
   1. Mariette X,
   2. Kivitz A,
   3. Isaacs JD,
   4. Stohl W,
   5. Tak PP,
   6. Jones RE,
   7. et al.

   Effectiveness of rituximab (RTX) + methotrexate (MTX) in patients (PTS) with early active rheumatoid arthritis (RA) and disease characteristics associated with poor outcomes [abstract]. Arthritis Rheum 2009;60 Suppl:1687.

   OpenUrl
2. 2.↵
   1. Isaacs JD,
   2. Olech E,
   3. Tak PP,
   4. Deodhar A,
   5. Keystone E,
   6. Emery P,
   7. et al.

   Autoantibody-positive rheumatoid arthritis (RA) patients (PTS) have enhanced clinical response to rituximab (RTX) when compared with seronegative patients [abstract]. Ann Rheum Dis 2009;68 Suppl:442

   OpenUrlFREE Full Text
3. 3.↵
   1. Tak PP,
   2. Cohen SB,
   3. Emery P,
   4. Saadeh CK,
   5. De Vita S,
   6. Donohue JP,
   7. et al.

   Clinical response following the first treatment course with rituximab: Effect of baseline autoantibody status (RF, anti-CCP) [abstract]. Ann Rheum Dis 2007;66 Suppl:338.

   OpenUrl
4. 4.↵
   1. Potter C,
   2. Hyrich KL,
   3. Tracey A,
   4. Lunt M,
   5. Plant D,
   6. Symmons DP,
   7. et al.

   Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis 2009;68:69–74.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Stuhlmuller B,
   2. Haupl T,
   3. Hernandez MM,
   4. Grutzkau A,
   5. Kuban RJ,
   6. Tandon N,
   7. et al.

   CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis. Clin Pharmacol Ther 2010;87:311–21.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Tsuzaka K,
   2. Itami Y,
   3. Takeuchi T,
   4. Sinozaki N,
   5. Morishita T

   . ADAMTS5 is a biomarker for prediction of response to infliximab in patients with rheumatoid arthritis. J Rheumatol 2010;37:1454–60.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Apte SS

   . A disintegrin-like and metalloprotease (reprolysin-type) with thrombospondin type 1 motif (ADAMTS) superfamily: functions and mechanisms. J Biol Chem 2009;284:31493–7.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Jones GC,
   2. Riley GP

   . ADAMTS proteinases: a multi-domain, multi-functional family with roles in extracellular matrix turnover and arthritis. Arthritis Res Ther 2005;7:160–9.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Colige A,
   2. Sieron AL,
   3. Li SW,
   4. Schwarze U,
   5. Petty E,
   6. Wertelecki W,
   7. et al.

   Human Ehlers-Danlos syndrome type VII C and bovine dermatosparaxis are caused by mutations in the procollagen I N-proteinase gene. Am J Hum Genet 1999;65:308–17.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Lapiere CM,
    2. Nusgens BV

    . Ehlers-Danlos type VII-C, or human dermatosparaxis. The offspring of a union between basic and clinical research. Arch Dermatol 1993;129:1316–9.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Levy GG,
    2. Nichols WC,
    3. Lian EC,
    4. Foroud T,
    5. McClintick JN,
    6. McGee BM,
    7. et al.

    Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001;413:488–94.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Zheng X,
    2. Chung D,
    3. Takayama TK,
    4. Majerus EM,
    5. Sadler JE,
    6. Fujikawa K

    . Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001;276:41059–63.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Glasson SS,
    2. Askew R,
    3. Sheppard B,
    4. Carito BA,
    5. Blanchet T,
    6. Ma HL,
    7. et al.

    Characterization of and osteoarthritis susceptibility in ADAMTS-4-knockout mice. Arthritis Rheum 2004;50:2547–58.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Glasson SS,
    2. Askew R,
    3. Sheppard B,
    4. Carito B,
    5. Blanchet T,
    6. Ma HL,
    7. et al.

    Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 2005;434:644–8.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Stanton H,
    2. Rogerson FM,
    3. East CJ,
    4. Golub SB,
    5. Lawlor KE,
    6. Meeker CT,
    7. et al.

    ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature 2005;434:648–52.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Yamanishi Y,
    2. Boyle DL,
    3. Clark M,
    4. Maki RA,
    5. Tortorella MD,
    6. Arner EC,
    7. et al.

    Expression and regulation of aggrecanase in arthritis: the role of TGF-beta. J Immunol 2002;168:1405–12.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Koshy PJ,
    2. Lundy CJ,
    3. Rowan AD,
    4. Porter S,
    5. Edwards DR,
    6. Hogan A,
    7. et al.

    The modulation of matrix metalloproteinase and ADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M: a time-course study using real-time quantitative reverse transcription-polymerase chain reaction. Arthritis Rheum 2002;46:961–7.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Pratta MA,
    2. Scherle PA,
    3. Yang G,
    4. Liu RQ,
    5. Newton RC

    . Induction of aggrecanase 1 (ADAM-TS4) by interleukin-1 occurs through activation of constitutively produced protein. Arthritis Rheum 2003;48:119–33.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Bondeson J,
    2. Wainwright SD,
    3. Lauder S,
    4. Amos N,
    5. Hughes CE

    . The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis. Arthritis Res Ther 2006;8:R187.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Liu CJ,
    2. Kong W,
    3. Ilalov K,
    4. Yu S,
    5. Xu K,
    6. Prazak L,
    7. et al.

    ADAMTS-7: a metalloproteinase that directly binds to and degrades cartilage oligomeric matrix protein. Faseb J 2006; 20:988–90.

    OpenUrlAbstract/FREE Full Text
21. 21.↵
    1. Luan Y,
    2. Kong L,
    3. Howell DR,
    4. Ilalov K,
    5. Fajardo M,
    6. Bai XH,
    7. et al.

    Inhibition of ADAMTS-7 and ADAMTS-12 degradation of cartilage oligomeric matrix protein by alpha-2-macroglobulin. Osteoarthritis Cartilage 2008;16:1413–20.

    OpenUrlCrossRefPubMed